Study met primary end point and demonstrated successful subcutaneous administration of a 10 mL biologic co-formulated with ENHANZE® in 30 seconds using Halozyme's proprietary high-volume auto-injector ...
Subcutaneous immunotherapy injections work the same way as their intravenous counterparts — by changing or enhancing a person’s immune responses to cancer. Immunotherapy for cancer is a broad category ...
IMscin001 study showed non-inferior levels of cancer immunotherapy Tecentriq in the blood, when injected subcutaneously, compared to intravenous infusion, in people with advanced non-small cell lung ...
Roche has shared the data that it hopes will secure approval for a subcutaneous formulation of its PD-L1 checkpoint inhibitor Tecentriq. Having revealed the top-line success in August, the Swiss ...
CINCINNATI, April 25, 2025 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”), a healthcare innovation company developing and manufacturing the enFuse ® wearable drug delivery platform, announced ...
LONDON & SAN DIEGO--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, and ...
Roche has taken the lead in the race to bring subcutaneous checkpoint inhibitors to market in the West, reporting phase 3 results that tee it up to file for approval in the U.S. and the EU. The ...
Technology that was developed to produce energy-dense rocket fuel has been adapted to produce protein-dense therapeutic formulations. Such formulations are expected to reach new heights, escaping the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback